相似文献
1
Design and engineering of deimmunized biotherapeutics.
Curr Opin Struct Biol. 2016 Aug;39:79-88. doi: 10.1016/j.sbi.2016.06.003. Epub 2016 Jun 17.
2
EpiSweep: Computationally Driven Reengineering of Therapeutic Proteins to Reduce Immunogenicity While Maintaining Function.
Methods Mol Biol. 2017;1529:375-398. doi: 10.1007/978-1-4939-6637-0_20.
3
Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate.
Cell Mol Life Sci. 2014 Dec;71(24):4869-80. doi: 10.1007/s00018-014-1652-x. Epub 2014 Jun 1.
4
Mapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidate.
PLoS Comput Biol. 2015 Jan 8;11(1):e1003988. doi: 10.1371/journal.pcbi.1003988. eCollection 2015 Jan.
5
MHCEpitopeEnergy, a Flexible Rosetta-Based Biotherapeutic Deimmunization Platform.
J Chem Inf Model. 2021 May 24;61(5):2368-2382. doi: 10.1021/acs.jcim.1c00056. Epub 2021 Apr 26.
6
Design and analysis of immune-evading enzymes for ADEPT therapy.
Protein Eng Des Sel. 2012 Oct;25(10):613-23. doi: 10.1093/protein/gzs044. Epub 2012 Aug 16.
7
New approaches to prediction of immune responses to therapeutic proteins during preclinical development.
Drugs R D. 2008;9(6):385-96. doi: 10.2165/0126839-200809060-00004.
8
Structure-based redesign of proteins for minimal T-cell epitope content.
J Comput Chem. 2013 Apr 5;34(10):879-91. doi: 10.1002/jcc.23213. Epub 2013 Jan 8.
9
Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem.
Protein Eng Des Sel. 2020 Sep 14;33. doi: 10.1093/protein/gzaa025.
10
Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads.
Biotechnol Bioeng. 2015 Jul;112(7):1306-18. doi: 10.1002/bit.25554. Epub 2015 Feb 23.
引用本文的文献
1
Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases.
Pharmaceutics. 2025 May 2;17(5):606. doi: 10.3390/pharmaceutics17050606.
2
A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation.
Int J Nanomedicine. 2025 Feb 26;20:2445-2460. doi: 10.2147/IJN.S499192. eCollection 2025.
3
Robust genome and cell engineering via in vitro and in situ circularized RNAs.
Nat Biomed Eng. 2025 Jan;9(1):109-126. doi: 10.1038/s41551-024-01245-z. Epub 2024 Aug 26.
4
Robust Prediction of Relative Binding Energies for Protein-Protein Complex Mutations Using Free Energy Perturbation Calculations.
J Mol Biol. 2024 Aug 15;436(16):168640. doi: 10.1016/j.jmb.2024.168640. Epub 2024 Jun 4.
5
Robust prediction of relative binding energies for protein-protein complex mutations using free energy perturbation calculations.
bioRxiv. 2024 Apr 24:2024.04.22.590325. doi: 10.1101/2024.04.22.590325.
6
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies.
BioDrugs. 2024 Mar;38(2):205-226. doi: 10.1007/s40259-023-00641-2. Epub 2024 Jan 23.
7
Accelerating therapeutic protein design with computational approaches toward the clinical stage.
Comput Struct Biotechnol J. 2023 Apr 29;21:2909-2926. doi: 10.1016/j.csbj.2023.04.027. eCollection 2023.
8
Functional Deimmunization of Botulinum Neurotoxin Protease Domain via Computationally Driven Library Design and Ultrahigh-Throughput Screening.
ACS Synth Biol. 2023 Jan 20;12(1):153-163. doi: 10.1021/acssynbio.2c00426. Epub 2023 Jan 9.
9
Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.
Cell Syst. 2022 Oct 19;13(10):830-843.e3. doi: 10.1016/j.cels.2022.09.003.
10
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
本文引用的文献
1
Computationally driven antibody engineering enables simultaneous humanization and thermostabilization.
Protein Eng Des Sel. 2016 Oct;29(10):419-426. doi: 10.1093/protein/gzw024. Epub 2016 Jun 21.
2
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Oncotarget. 2016 May 24;7(21):29916-26. doi: 10.18632/oncotarget.9171.
3
Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.
J Pharm Sci. 2016 May;105(5):1567-1575. doi: 10.1016/j.xphs.2016.02.031. Epub 2016 Apr 1.
4
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.
Front Immunol. 2016 Feb 2;7:21. doi: 10.3389/fimmu.2016.00021. eCollection 2016.
5
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
J Pharm Sci. 2016 Feb;105(2):460-475. doi: 10.1016/j.xphs.2015.11.015.
6
Immunogenicity of Therapeutic Protein Aggregates.
J Pharm Sci. 2016 Feb;105(2):417-430. doi: 10.1016/j.xphs.2015.11.002.
7
Engineering less immunogenic and antigenic FVIII proteins.
Cell Immunol. 2016 Mar;301:12-7. doi: 10.1016/j.cellimm.2015.10.008. Epub 2015 Nov 2.
8
DNA shuffling of uricase gene leads to a more "human like" chimeric uricase with increased uricolytic activity.
Int J Biol Macromol. 2016 Jan;82:522-9. doi: 10.1016/j.ijbiomac.2015.10.053. Epub 2015 Oct 23.
9
Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development.
Toxins (Basel). 2015 Oct 10;7(10):4067-82. doi: 10.3390/toxins7104067.
10
Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
PLoS One. 2015 Sep 15;10(9):e0138123. doi: 10.1371/journal.pone.0138123. eCollection 2015.
Zotero 插件